“谈成了！”原价百万1针的CAR-T有望纳入创新药目录

Core Insights - The negotiation for the 2025 National Medical Insurance (NMI) has reached its fourth day, with significant developments in the discussions regarding innovative drugs [2] - The negotiation for commercial insurance innovative drug catalog has officially begun, with a successful outcome for Huyuan Biotech's CAR-T therapy [3] Group 1: Negotiation Outcomes - Huyuan Biotech's CAR-T drug, previously priced at 999,000 yuan (approximately 99.9 million), is now the lowest-priced CAR-T therapy in China [3] - The CEO of Huyuan Biotech, Lv Lulu, confirmed the successful negotiation with a positive response when asked about the outcome [3] Group 2: Industry Context - CAR-T therapies are known for their high costs, typically around 1 million yuan per injection, and even with discounts, the price remains around 500,000 yuan [3] - Previous attempts to include CAR-T therapies in the basic medical insurance catalog have failed multiple times over the past few years [3]